To access the full text documents, please follow this link: http://hdl.handle.net/2445/102125
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Ellis, Matthew J. |
dc.contributor.author | Suman, Vera J. |
dc.contributor.author | Hoog, Jeremy |
dc.contributor.author | Lin, Li |
dc.contributor.author | Snider, Jacqueline |
dc.contributor.author | Prat Aparicio, Aleix |
dc.contributor.author | Parker, Joel S. |
dc.contributor.author | Luo, Jingqin |
dc.contributor.author | DeSchryver, Katherine |
dc.contributor.author | Allred, D.Craig |
dc.contributor.author | Esserman, Laura J. |
dc.contributor.author | Unzeitig, Gary W. |
dc.contributor.author | Margenthaler, Julie |
dc.contributor.author | Babiera, Gildy V. |
dc.contributor.author | Marcom, P. Kelly |
dc.contributor.author | Guenther, Joseph M. |
dc.contributor.author | Watson, Mark A. |
dc.contributor.author | Leitch, Marylin |
dc.contributor.author | Hunt, Kelly |
dc.contributor.author | Olson, John A. |
dc.date | 2016-09-26T07:22:26Z |
dc.date | 2016-09-26T07:22:26Z |
dc.date | 2011-06-10 |
dc.date | 2016-09-26T07:22:31Z |
dc.identifier.citation | 0732-183X |
dc.identifier.citation | 660925 |
dc.identifier.uri | http://hdl.handle.net/2445/102125 |
dc.format | 8 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation | Reproducció del document publicat a: http://dx.doi.org/10.1200/JCO.2010.31.6950 |
dc.relation | Journal of Clinical Oncology, 2011, vol. 29, num. 17, p. 2342-2349 |
dc.relation | http://dx.doi.org/10.1200/JCO.2010.31.6950 |
dc.rights | (c) American Society of Clinical Oncology, 2011 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Càncer de mama |
dc.subject | Receptors d'hormones |
dc.subject | Estrògens |
dc.subject | Menopausa |
dc.subject | Assaigs clínics de medicaments |
dc.subject | Breast cancer |
dc.subject | Hormone receptors |
dc.subject | Estrogen |
dc.subject | Menopause |
dc.subject | Drug testing |
dc.title | Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype -ACOSOG Z1031 |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |